INT7336

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.70
First Reported 1984
Last Reported 2011
Negated 2
Speculated 2
Reported most in Abstract
Documents 60
Total Number 66
Disease Relevance 24.20
Pain Relevance 19.62

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular region (VIP)
Anatomy Link Frequency
plasma 12
neurons 9
SH-SY5Y 2
tears 2
nasal 2
VIP (Homo sapiens)
Pain Link Frequency Relevance Heat
substance P 226 100.00 Very High Very High Very High
Neuropeptide 167 100.00 Very High Very High Very High
Neurotransmitter 31 100.00 Very High Very High Very High
Calcitonin gene-related peptide 5 100.00 Very High Very High Very High
transcutaneous nerve stimulation 70 99.86 Very High Very High Very High
psoriasis 92 99.68 Very High Very High Very High
Angina 16 99.48 Very High Very High Very High
nMDA receptor antagonist 30 99.16 Very High Very High Very High
Central nervous system 33 99.12 Very High Very High Very High
Pain 18 99.00 Very High Very High Very High
Disease Link Frequency Relevance Heat
Hypersensitivity 239 100.00 Very High Very High Very High
Alzheimer's Dementia 5 100.00 Very High Very High Very High
Heart Rate Under Development 4 100.00 Very High Very High Very High
Esophageal Cancer 1 99.76 Very High Very High Very High
Psoriasis 106 99.68 Very High Very High Very High
Schizophrenia 61 99.60 Very High Very High Very High
Cv General 3 Under Development 28 99.48 Very High Very High Very High
Rheumatoid Arthritis 14 99.48 Very High Very High Very High
Increased Venous Pressure Under Development 84 99.40 Very High Very High Very High
Diarrhoea 33 99.12 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We have previously shown that plasma vasoactive intestinal polypeptide (VIP) is increased in normal subjects by low-frequency transcutaneous nerve stimulation.
Positive_regulation (increased) of VIP in plasma associated with transcutaneous nerve stimulation
1) Confidence 0.70 Published 1986 Journal Gen. Pharmacol. Section Abstract Doc Link 3721187 Disease Relevance 0.07 Pain Relevance 0.17
Pretreatment of SH-SY5Y cells with 10 microM RA over 6 days dramatically increased VIP receptor number from approximately 3,000 to approximately 70,000 sites per cell and enhanced threefold the cAMP accumulation after external VIP addition, while VIP immunoreactive content in the cells increased 2-3-fold.
Positive_regulation (increased) of VIP in SH-SY5Y associated with rheumatoid arthritis
2) Confidence 0.69 Published 1989 Journal FEBS Lett. Section Abstract Doc Link 2546814 Disease Relevance 0.68 Pain Relevance 0.09
Distribution and staining intensity of ME, NPY and NT in the amygdala showed no qualitatively recognizable difference between the normal and schizophrenic specimens, whereas VIP-IR appeared to be slightly increased in the central amygdaloid nucleus of schizophrenics.
Positive_regulation (increased) of VIP in amygdala associated with enkephalin, amygdala and schizophrenia
3) Confidence 0.67 Published 1986 Journal Acta Neuropathol. Section Abstract Doc Link 2948368 Disease Relevance 0.25 Pain Relevance 0.62
Depolarization of sympathetic neuron cultures with elevated potassium elicited a different spectrum of effects; it increased VIP and NPY content but did not alter substance P, somatostatin, or L-Enk.
Neg (not) Positive_regulation (increased) of VIP in neuron associated with somatostatin and substance p
4) Confidence 0.67 Published 1992 Journal Dev. Biol. Section Abstract Doc Link 1372570 Disease Relevance 0.07 Pain Relevance 0.58
In conclusion, PACAP peptides and VIP mediate their relaxant effects via activation of specific PACAP and VIP receptors coupled to different potassium channels.
Positive_regulation (activation) of VIP associated with potassium channel
5) Confidence 0.67 Published 1993 Journal Scand. J. Gastroenterol. Section Abstract Doc Link 8362218 Disease Relevance 0 Pain Relevance 0.14
However, using a “paired Wilcoxon Rank test” for statistical analysis –which analyses the magnitude of the difference in paired samples– allowed us to convincingly demonstrate the increase of SP, CGRP and VIP tear levels after CPT only in eyes challenged with allergen.
Positive_regulation (increase) of VIP in eyes associated with substance p
6) Confidence 0.61 Published 2011 Journal Molecular Vision Section Body Doc Link PMC3021574 Disease Relevance 0.92 Pain Relevance 0.32
Increase in plasma vasoactive intestinal polypeptide (VIP) in muscular exercise in humans.
Positive_regulation (Increase) of VIP in plasma
7) Confidence 0.61 Published 1986 Journal Gen. Pharmacol. Section Title Doc Link 3721187 Disease Relevance 0.14 Pain Relevance 0.23
Vasoactive intestinal peptide (VIP) is the most probable candidate for such a factor since VIP is the only neurotransmitter the extracellular level of which increases during SPs exacerbation and decreases in remission.
Positive_regulation (increases) of VIP associated with psoriasis and neurotransmitter
8) Confidence 0.60 Published 2009 Journal Med. Hypotheses Section Abstract Doc Link 18926642 Disease Relevance 0.85 Pain Relevance 0.28
A possible source of this increased plasma VIP following TNS is the central nervous system.
Spec (possible) Positive_regulation (increased) of VIP in central nervous system associated with central nervous system and transcutaneous nerve stimulation
9) Confidence 0.57 Published 1984 Journal Gen. Pharmacol. Section Abstract Doc Link 6335447 Disease Relevance 0.17 Pain Relevance 0.52
It is concluded that the stimulation-induced increase in plasma VIP is due to release of VIP outside the brain.
Positive_regulation (increase) of VIP in plasma
10) Confidence 0.57 Published 1984 Journal Gen. Pharmacol. Section Abstract Doc Link 6335447 Disease Relevance 0.16 Pain Relevance 0.46
Our results show a significant increase of SP, CGRP, and VIP tear levels after challenge with allergen –but not with diluent– and no significant changes at baseline and after challenge between CPT eyes and control eyes.
Positive_regulation (increase) of VIP in eyes associated with substance p
11) Confidence 0.53 Published 2011 Journal Molecular Vision Section Body Doc Link PMC3021574 Disease Relevance 0.71 Pain Relevance 0.37
Our findings are in line with evidence demonstrating an increase of SP, CGRP, and VIP after nasal allergen challenge and in airway hyperresponsiveness [16,31,32].
Positive_regulation (increase) of VIP in nasal associated with substance p
12) Confidence 0.53 Published 2011 Journal Molecular Vision Section Body Doc Link PMC3021574 Disease Relevance 1.18 Pain Relevance 0.24
We have also studied a related peptide, peptide histidine methionine (PHM), which coexists with VIP in human airway nerves, and in separate experiments studied fragments of the VIP amino acid sequence (VIP1-10 and VIP16-28) for agonist and antagonist activity.
Positive_regulation (fragments) of VIP in nerves associated with antagonist and agonist
13) Confidence 0.50 Published 1986 Journal J. Appl. Physiol. Section Abstract Doc Link 3781947 Disease Relevance 0 Pain Relevance 0.27
PACAP 1-38 (10(-9) M) increased substance P (SP), gastrin releasing peptide (GRP) and VIP release.
Positive_regulation (increased) of VIP associated with substance p
14) Confidence 0.49 Published 2001 Journal Regul. Pept. Section Abstract Doc Link 11495686 Disease Relevance 0 Pain Relevance 0.49
This is associated with a moderate but significant increase of 30-35% in the concentration of the vasoactive intestinal polypeptide (VIP) in the cubital vein plasma.
Positive_regulation (increase) of VIP in cubital vein
15) Confidence 0.47 Published 1984 Journal Gen. Pharmacol. Section Abstract Doc Link 6335447 Disease Relevance 0.17 Pain Relevance 0.51
In the group of healthy subjects, ergometer exercises with progressive increases in workload until exhaustion, lasting from 16 to 32 min (mean 26 min) and with a corresponding maximum energy output of 1500 to 5100 W (mean 3560 W), resulted in an increase in plasma VIP concentration from a pre-stimulatory level of 3.3 pmol . l-1 to 5.3, 5.2 and 5.6 pmol . l-1, measured 3, 10 and 20 min respectively, following termination of the exercise, i.e. a maximal 70% increase.
Positive_regulation (increase) of VIP in plasma
16) Confidence 0.47 Published 1986 Journal Gen. Pharmacol. Section Abstract Doc Link 3721187 Disease Relevance 0.17 Pain Relevance 0.24
The presence of both VIP binding sites on fetal vascularization and VIP-induced adenylate cyclase activation would seem to suggest a regulatory role of the peptide on fetoplacental blood flow.
Positive_regulation (activation) of VIP-induced in blood
17) Confidence 0.47 Published 1987 Journal Regul. Pept. Section Abstract Doc Link 2829291 Disease Relevance 0 Pain Relevance 0.10
Plasma VIP was significantly higher on a VIP day compared with placebo (AUC(0-80 min), P < 0.001).
Positive_regulation (higher) of VIP in Plasma
18) Confidence 0.46 Published 2006 Journal Cephalalgia Section Abstract Doc Link 16886936 Disease Relevance 0.35 Pain Relevance 0.33
Morphological changes induced by S. flexneri but not the increase in VIP-IR were blocked by the NMDA receptor antagonist MK-801.
Positive_regulation (increase) of VIP-IR associated with nmda receptor antagonist
19) Confidence 0.46 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2653194 Disease Relevance 0.58 Pain Relevance 0.05
The increase in the proportion of VIP-IR neurons observed in this study is probably more to be associated with neurodegenerative processes than to changes in neuronal phenotype.
Positive_regulation (increase) of VIP-IR in neurons associated with neurodegenerative disease
20) Confidence 0.46 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2653194 Disease Relevance 0.58 Pain Relevance 0.22

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox